gilead return growth least temporarili share
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim may
price data may
rate updat may
currenc amount express
methodolog valu compani
maintain per share fair valu estim
gilead follow solid first-quart result
encourag first earn call new ceo daniel day
overal expect gilead focu defend hiv
franchis allow kite innov separ oncolog
cell therapi busi unit maxim potenti launch
immunolog drug filgotinib partner nash
continu test new combin regimen total revenu
grew first quarter first quarter year-over-
year growth three year hiv growth
yescarta launch abl counter declin
hepat revenu top-lin growth like dip
neg year gilead continu fight
hepat declin also lose cardiopulmonari drug
letairi ranexa gener competit think share
incorpor overli pessimist long-term evolut
firm pipelin continu view firm hiv
hcv portfolio well emerg oncolog
immunolog pipelin support stabl wide moat
hiv sale declin sequenti million
headwind due inventori drawdown payer mix
biktarvi launch continu impress rate
million sale quarter solidifi rank
top hiv treatment new switch patient howev
gilead contend new competit
glaxo two-drug regimen dovato approv
april list price biktarvi
gilead steal share glaxo sinc
biktarvi launch expect market share stabil
dovato launch particularli long-term data continu
support efficaci two-drug regimen
gilead truvada continu see strong uptak pre-
exposur prophylaxi therapi total
million patient target market accord cdc
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
develop market therapi treat life-threaten
infecti diseas core portfolio focus hiv
hepat acquisit coru pharma myogen cv
therapeut arresto bioscienc calistoga broaden focu
includ pulmonari cardiovascular diseas cancer gilead
acquisit pharmasset brought right hepat drug sovaldi
also part combin drug harvoni kite acquisit boost
gilead exposur cell therapi oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
expand collabor space gilead novo
nordisk begin proof-of-concept studi combin
novo oral semaglutid cilofexor
firsocostat insitro partnership focus discov
new nash target insitro platform
estim march head head studi descovi
versu truvada show descovi non-inferior
efficaci offer better renal bone safeti profil
gilead expect descovi approv indic
fourth quarter see safeti benefit
rel modest leav room gener truvada
compet indic
beyond hiv gilead yescarta sale grow
reimburs improv center train
administ car-t therapi see
competit area encourag gilead decis
move off-the-shelf car-t therapi develop
would like significantli lower cost
product elimin patient wait time
gilead promis pipelin therapi filgotinib
produc strong phase data rheumatoid arthriti
file europ year gilead meet
fda determin time file think
testicular safeti data may avail next year
expect gilead hope clean safeti profil
safeti label base recent phase data also see
gilead long-term player nash intern
combin regimen well new partnership
help firm build portfolio albeit long run
wake selonsertib failur two phase studi
nash gilead focus phase studi
combin
remain two advanc drug
candid diseas fxr agonist cilofexor
inhibitor firsocostat data easl april show data
combin small studi improv hepat
steatosi reduc liver fat appar driven firsocostat
well reduc liver stiff reduc fibrosi
improv liver biochemistri driven compound
safeti profil also encourag seriou side
effect deem treatment-rel gilead also recent
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
